CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-02-07
DOI
10.1038/s41467-020-14619-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-bet promotes potent antitumor activity of CD4+ CAR T cells
- (2018) Albert T Gacerez et al. CANCER GENE THERAPY
- Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles
- (2018) David F. Tucker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance
- (2015) Giovanni Carulli et al. ACTA HAEMATOLOGICA
- A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
- (2015) M. Mamonkin et al. BLOOD
- Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases
- (2015) Fanny Pojero et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents
- (2015) Vittorio Emanuele Muccio et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
- (2015) Sara Yousef et al. Human Vaccines & Immunotherapeutics
- Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
- (2012) K. Boucher et al. CLINICAL CANCER RESEARCH
- Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
- (2011) D. Atanackovic et al. HAEMATOLOGICA
- Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
- (2011) Ole Audun Werner Haabeth et al. Nature Communications
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now